Four oncologists from the Sarah Cannon Research Institute in Tennessee shared with Fox News Digital what they see as the most ...

Non-Hodgkin lymphomas can be classified according to the speed at which they progress. Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is ...

Bone marrow transplants, long a mainstay of blood cancer treatments, are becoming less common in favor of options like CAR-T ...

T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...

Chimeric antigen receptor T-cell or CAR T therapy shows promise for patients with refractory or relapsing B-cell lymphomas.

The global market for intraocular lymphoma therapy is expected to be worth USD 1.2 billion by the year of 2023. The market, ...

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas ...

Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and ...

Preliminary data from the first-in-human study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that CS5001 is well-tolerated and exhibits encouraging ...

"Because it inhibits the Bcl-2 proteins associated with poor response to existing therapies for B-cell lymphomas, we expected that venetoclax would have a direct impact on CAR T cell populations ...